Bamco Inc. NY acquired a new position in Heartflow, Inc. (NASDAQ:HTFL - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,225,133 shares of the company's stock, valued at approximately $94,625,000. Bamco Inc. NY owned 3.74% of Heartflow as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow in the fourth quarter valued at about $27,000. Russell Investments Group Ltd. bought a new stake in Heartflow in the fourth quarter worth $45,000. Essential Partners LLC bought a new position in shares of Heartflow in the 1st quarter valued at about $57,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 3rd quarter valued at approximately $59,000. Finally, Strs Ohio purchased a new position in shares of Heartflow in the 4th quarter worth approximately $99,000.
Heartflow Trading Down 1.9%
Shares of NASDAQ:HTFL opened at $48.94 on Thursday. The company has a market capitalization of $4.26 billion and a PE ratio of -26.74. The business has a 50 day moving average of $31.68 and a two-hundred day moving average of $28.79. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $51.19.
Heartflow (NASDAQ:HTFL - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The firm had revenue of $64.08 million for the quarter. Heartflow's revenue was up 47.7% compared to the same quarter last year. Equities research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on HTFL shares. Weiss Ratings upgraded Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Morgan Stanley raised their price target on shares of Heartflow from $35.00 to $40.00 and gave the stock an "equal weight" rating in a research note on Friday, August 14th. JPMorgan Chase & Co. upped their target price on Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a report on Friday, August 14th. Benchmark reiterated a "buy" rating on shares of Heartflow in a research note on Friday, August 14th. Finally, Robert W. Baird set a $45.00 target price on shares of Heartflow in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $43.43.
Get Our Latest Analysis on Heartflow
Insider Activity
In related news, insider Campbell Rogers sold 9,219 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $41.23, for a total value of $380,099.37. Following the completion of the transaction, the insider owned 86,459 shares of the company's stock, valued at approximately $3,564,704.57. This represents a 9.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00. Following the transaction, the chief executive officer owned 457,935 shares in the company, valued at $16,027,725. This represents a 7.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 191,271 shares of company stock valued at $7,089,136. 7.70% of the stock is owned by company insiders.
About Heartflow
(
Free Report)
HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Articles
Want to see what other hedge funds are holding HTFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heartflow, Inc. (NASDAQ:HTFL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Heartflow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list.
While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.